1Mok TS Zee B Chan AT et al.A phase Ⅱ study of gemcitabine plus oral etoposide in the treatment of patients with advanced non-small cell lung carcinoma [J].Cancer,2000,89(3):543-550.
2[1]Lebwohl D , Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update[J]. Eur J Cancer, 1998,34(10): 1522-1534.
3[2]Muramatsu S, Ku Y, Kuroda Y. Pharmaeokinetic comparison between cisplatin and nedaplatin in hepatic arterial chemotherapy using complete hepatic venous isolation and charcoal hemoperfusion[J]. Jpn J Cancer Chemother,1998,25(9): 1457-1460.
4[3]Kawanishi K, Miyagi Y, Yamamoto J, et al. Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters[J]. Cancer Chemother Pharmacol,2001,47(4): 303-308.
5[4]Fujii M, Tokumaru Y, Imanishi Y, et al. Combination chemotherapy with nedaplatin and 5-FU for head neck cancer[J]. Jpn J Cancer Chemother, 1998, 25(1):53-58.
6[5]Sasaoka M, Fuua N, Matsumoto A, et al. Alternating chemoradiotherapy for oropharyngeal cancer [J]. Jpm J Cancer Chemother, 2000; 27(14): 2217-2221.
7[6]Takeda Y, Kasai H, Uchida N, et al. Enhanced antitumor efficacy of nedaplatin with 5-fluorouracil against human squamous carcinoma xenografts [J]. Anticancer Res, 1999,19 (5B): 4059-4064.
8[7]Yoshioka T, Gamoh M, Shineha R, et al. A new combimation chemotherapy with cis- diammine- glycolatoplatinum (nedaplatin) and 5-fluorouracil for advanced esoiphageal cancers[J]. Intern Med, 1999, 38(11) :844-848.
9[8]Hirata S, Yatsuyanagi E, Yamazaki H, et al. Neoadjuvant chemotherapy for esophageal cancer by administration of nedaplatin alone[J]. Jpm J Cancer Chemother, 2000, (2):221-226.
10[9]Sumi H, Ohtsu A, Boku N, et al. A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemradiotherapy including nedaplatin[J]. Jpn J Clin Oncol, 2000, 30(9):406-409.
4Sheth S. Current and emerging therapies for patients with advanced non-small-cell lung cancer[J].American journal of health-system pharma-cy,2010,(01):S9-S14.
5Treat J,Scagliotti G V,Peng G. Comparison of pemetrexed plus cispl-atin with other first-line doublets in advanced non-small cell lung canc-er (NSCLC):A combined analysis of three phase 3 trials[J].Lung canc-er,2012,(02):222-227.
6Kim HK, Choi YS,Kim J, et al. Outcomes of unexpectedpathologic N1 and N2 disease after video-assisted thoracicsurgery lobectomy for clinical stage I non-small cell lungcancer[J]. J Thorac Cardiovasc Surg,2010,140(6) : 1288-1293.
7Kim K, Kim HK? Park JS, et al. Video-assisted thoracicsurgery lobectomy : single institutional experience with704 cases[J], Ann Thorac Surg,2010,89(6) :2118-2122.
8Rueth NM, Andrade RS. Is VATS lobectomy better:peri-operatively, biologically and oncologically[J], Ann ThoracSurg,2010,89(6):2107-2111.
9Boyd J A, Hubbs JL, Kim DW,et al. Timing of local anddistant failure in resected lung cancer ? implications for re-ported rates of local failure[J]. J Thorac Oncol, 2010, 5(2):211-214.
